Chongqing Zhifei Bio Products
Chongqing Zhifei Biological Products Co., Ltd. engages in the research and development, production, marketing, distribution, import, and export of vaccines in China. The company offers Recombinant Novel Coronavirus Vaccine (CHO Cell); Recombinant Mycobacterium Tuberculosis Fusion Protein under the Ekear brand; Haemophilus Influenzae Type b Vaccine under the XiFeiBei brand; ACYW135 Meningococcal P… Read more
Chongqing Zhifei Bio Products (300122) - Net Assets
Latest net assets as of September 2025: CN¥29.61 Billion CNY
Based on the latest financial reports, Chongqing Zhifei Bio Products (300122) has net assets worth CN¥29.61 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥46.39 Billion) and total liabilities (CN¥16.79 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥29.61 Billion |
| % of Total Assets | 63.82% |
| Annual Growth Rate | 34.98% |
| 5-Year Change | 273.77% |
| 10-Year Change | 1148.6% |
| Growth Volatility | 86.64 |
Chongqing Zhifei Bio Products - Net Assets Trend (2007–2024)
This chart illustrates how Chongqing Zhifei Bio Products's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Chongqing Zhifei Bio Products (2007–2024)
The table below shows the annual net assets of Chongqing Zhifei Bio Products from 2007 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥30.83 Billion | -2.14% |
| 2023-12-31 | CN¥31.51 Billion | +30.00% |
| 2022-12-31 | CN¥24.24 Billion | +37.26% |
| 2021-12-31 | CN¥17.66 Billion | +114.06% |
| 2020-12-31 | CN¥8.25 Billion | +43.52% |
| 2019-12-31 | CN¥5.75 Billion | +37.47% |
| 2018-12-31 | CN¥4.18 Billion | +42.33% |
| 2017-12-31 | CN¥2.94 Billion | +16.51% |
| 2016-12-31 | CN¥2.52 Billion | +2.11% |
| 2015-12-31 | CN¥2.47 Billion | +0.47% |
| 2014-12-31 | CN¥2.46 Billion | +2.87% |
| 2013-12-31 | CN¥2.39 Billion | +0.56% |
| 2012-12-31 | CN¥2.38 Billion | +5.22% |
| 2011-12-31 | CN¥2.26 Billion | +5.43% |
| 2010-12-31 | CN¥2.14 Billion | +374.15% |
| 2009-12-31 | CN¥451.69 Million | +69.14% |
| 2008-12-31 | CN¥267.06 Million | +42.03% |
| 2007-12-31 | CN¥188.03 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Chongqing Zhifei Bio Products's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 16364.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥27.24 Billion | 88.35% |
| Common Stock | CN¥2.39 Billion | 7.76% |
| Other Components | CN¥1.20 Billion | 3.88% |
| Total Equity | CN¥30.83 Billion | 100.00% |
Chongqing Zhifei Bio Products Competitors by Market Cap
The table below lists competitors of Chongqing Zhifei Bio Products ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CSI Solar Co. Ltd. A
SHG:688472
|
$2.17 Billion |
|
Retail Opportunity Investments
NASDAQ:ROIC
|
$2.18 Billion |
|
Beijing GeoEnviron Engineering
SHG:603588
|
$2.18 Billion |
|
Codan Ltd
AU:CDA
|
$2.18 Billion |
|
Ebos Group Ltd
AU:EBO
|
$2.17 Billion |
|
Sh Belling
SHG:600171
|
$2.17 Billion |
|
Shanghai Jin Jiang International Hotels Development Co Ltd A
SHG:600754
|
$2.17 Billion |
|
Par Pacific Holdings Inc
NYSE:PARR
|
$2.17 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Chongqing Zhifei Bio Products's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 31,506,080,813 to 30,830,739,408, a change of -675,341,405 (-2.1%).
- Net income of 2,018,478,516 contributed positively to equity growth.
- Dividend payments of 2,527,812,210 reduced retained earnings.
- Share repurchases of 300,030,172 reduced equity.
- Other comprehensive income decreased equity by 1,200,000,000.
- Other factors increased equity by 1,334,022,461.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥2.02 Billion | +6.55% |
| Dividends Paid | CN¥2.53 Billion | -8.2% |
| Share Repurchases | CN¥300.03 Million | -0.97% |
| Other Comprehensive Income | CN¥-1.20 Billion | -3.89% |
| Other Changes | CN¥1.33 Billion | +4.33% |
| Total Change | CN¥- | -2.14% |
Book Value vs Market Value Analysis
This analysis compares Chongqing Zhifei Bio Products's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.26x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 193.03x to 1.26x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | CN¥0.08 | CN¥16.28 | x |
| 2008-12-31 | CN¥0.12 | CN¥16.28 | x |
| 2009-12-31 | CN¥0.20 | CN¥16.28 | x |
| 2010-12-31 | CN¥1.53 | CN¥16.28 | x |
| 2011-12-31 | CN¥1.43 | CN¥16.28 | x |
| 2012-12-31 | CN¥1.48 | CN¥16.28 | x |
| 2013-12-31 | CN¥1.48 | CN¥16.28 | x |
| 2014-12-31 | CN¥1.52 | CN¥16.28 | x |
| 2015-12-31 | CN¥1.55 | CN¥16.28 | x |
| 2016-12-31 | CN¥1.62 | CN¥16.28 | x |
| 2017-12-31 | CN¥1.84 | CN¥16.28 | x |
| 2018-12-31 | CN¥2.61 | CN¥16.28 | x |
| 2019-12-31 | CN¥3.59 | CN¥16.28 | x |
| 2020-12-31 | CN¥5.16 | CN¥16.28 | x |
| 2021-12-31 | CN¥11.04 | CN¥16.28 | x |
| 2022-12-31 | CN¥10.10 | CN¥16.28 | x |
| 2023-12-31 | CN¥13.13 | CN¥16.28 | x |
| 2024-12-31 | CN¥12.87 | CN¥16.28 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Chongqing Zhifei Bio Products utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.55%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 7.74%
- • Asset Turnover: 0.52x
- • Equity Multiplier: 1.62x
- Recent ROE (6.55%) is below the historical average (28.08%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 80.84% | 30.87% | 1.48x | 1.77x | CN¥133.21 Million |
| 2008 | 71.16% | 32.71% | 1.49x | 1.46x | CN¥163.35 Million |
| 2009 | 51.27% | 38.34% | 1.17x | 1.15x | CN¥186.42 Million |
| 2010 | 11.99% | 34.83% | 0.33x | 1.03x | CN¥42.62 Million |
| 2011 | 8.70% | 31.23% | 0.26x | 1.06x | CN¥-29.42 Million |
| 2012 | 9.05% | 28.28% | 0.30x | 1.06x | CN¥-22.56 Million |
| 2013 | 5.46% | 16.71% | 0.30x | 1.08x | CN¥-108.58 Million |
| 2014 | 6.02% | 18.48% | 0.30x | 1.10x | CN¥-97.77 Million |
| 2015 | 7.99% | 27.70% | 0.27x | 1.09x | CN¥-49.52 Million |
| 2016 | 1.29% | 7.29% | 0.16x | 1.07x | CN¥-219.61 Million |
| 2017 | 14.72% | 32.20% | 0.33x | 1.40x | CN¥138.52 Million |
| 2018 | 34.71% | 27.76% | 0.77x | 1.63x | CN¥1.03 Billion |
| 2019 | 41.17% | 22.35% | 0.97x | 1.90x | CN¥1.79 Billion |
| 2020 | 40.02% | 21.73% | 1.00x | 1.84x | CN¥2.48 Billion |
| 2021 | 57.82% | 33.30% | 1.02x | 1.70x | CN¥8.44 Billion |
| 2022 | 31.11% | 19.70% | 1.01x | 1.57x | CN¥5.12 Billion |
| 2023 | 25.61% | 15.25% | 1.05x | 1.59x | CN¥4.92 Billion |
| 2024 | 6.55% | 7.74% | 0.52x | 1.62x | CN¥-1.06 Billion |
Industry Comparison
This section compares Chongqing Zhifei Bio Products's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,043,310,248
- Average return on equity (ROE) among peers: 14.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Chongqing Zhifei Bio Products (300122) | CN¥29.61 Billion | 80.84% | 0.57x | $2.17 Billion |
| Shenzhen CAU Technology Co Ltd (000004) | $124.02 Million | 4.50% | 1.13x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $525.49 Million | 14.76% | 1.41x | $1.02 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $174.34 Million | 36.11% | 1.61x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $642.80 Million | -4.58% | 0.44x | $244.62 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.69 Billion | 3.06% | 0.97x | $850.04 Million |
| Hualan Biological EngineeringInc (002007) | $1.86 Billion | 32.78% | 0.08x | $2.00 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.09 Billion | 4.42% | 0.71x | $784.18 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $831.21 Million | 22.32% | 0.12x | $3.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $2.04 Billion | 5.44% | 0.31x | $398.99 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $456.61 Million | 23.20% | 0.29x | $347.95 Million |